Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid

June 23, 2011 updated by: Chulalongkorn University

99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study

The purpose of this trial is to see if the 99mTechnetium-MIBI SPECT-CT can be a tool for preoperative evaluation of cervical node metastasis in papillary thyroid cancer.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
    • Bangkok
      • Pathumwan, Bangkok, Thailand, 10330
        • King Chulalongkorn Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • papillary thyroid cancer

Exclusion Criteria:

  • pregnancy
  • Bleeding abnormality
  • Prior history of head and neck cancer
  • can not perform 99mTechnetium-MIBI SPECT-CT
  • can not perform 131I remnant Ablation
  • Prior any head and neck surgery within 3 months
  • Prior deep neck infection within 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 99mTc positive
99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
Radiation: 99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
Experimental: 99mTc Negative_Neck dissection
99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
Radiation: 99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
Experimental: 99mTc Negative_No neck dissection
99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
Radiation: 99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Diagnostic Tool Statistic (PPV , NPV , Sensitivity , Specificity , Accuracy )
Time Frame: 18 months
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chulalongkorn University

Investigators

  • Principal Investigator: Napadon Tangjaturonrasme, Otolaryngologist, Department of Otolaryngology , Faculty of Medicine , Chulalongkorn University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2010

Primary Completion (Anticipated)

October 1, 2011

Study Completion (Anticipated)

November 1, 2011

Study Registration Dates

First Submitted

September 24, 2009

First Submitted That Met QC Criteria

September 24, 2009

First Posted (Estimate)

September 25, 2009

Study Record Updates

Last Update Posted (Estimate)

June 27, 2011

Last Update Submitted That Met QC Criteria

June 23, 2011

Last Verified

June 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NapadonChula_01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Papillary Thyroid Cancer

Clinical Trials on 99mTc-MIBI SPECT-CT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe